RhinAer®, the comprehensive, non-invasive solution for chronic rhinitis, was recently featured in specialty clinical news outlet, Healio. The article highlighted the results of the RHINTRAC randomized controlled trial published in International Forum of Allergy & Rhinology, in which the RhinAer procedure was shown to be superior to the sham in reducing chronic rhinitis symptoms at 3 months.
The article also provided a progress update on the patients enrolled in the RHINTRAC trial, concluding that the benefits patients received from the RhinAer procedure were sustained through 12 months.
“This study is a prospective randomized controlled study with a sham control, which is considered the best evidence-based study one can do,” shared Masayoshi Takashima, MD, FACS, Chair of the Department of Otolaryngology, Head and Neck Surgery at Houston Methodist Hospital. “Our results showed that even up to 12 months, not only was there improvement in symptoms compared to the control arm, but also continued improvement of symptoms at 12 months compared to other timepoints.”
Jose Pablo Stolovitzky, MD, Adjunct Assistant Professor with the Department of Otolaryngology at Emory School of Medicine, reinforced the positive findings, stating, “Overall, the results of this study are very consistent with prior studies.” He continued, “It’s very interesting that the responder rate increased and chronic rhinitis symptoms, including nasal congestion and rhinorrhea, continued to improve over time, surpassing improvements seen at the initial 3-month evaluation period. This was also seen in the improvement of cough and postnasal drip, which are often associated with chronic rhinitis.”
The RHINTRAC trial will continue to follow patients through 24 months to confirm the long-term durability of the treatment effect.
For more information, check out the full article here.
Aerin Medical may provide links to third-party sites. The opinions and comments expressed on these third-party sites are their own. Aerin Medical does not claim any accuracy of third-party reporting.